Jasper Therapeutics, Inc. Class A

Stage 4 · Declining · week 3

As of Oct 22, 2026, Jasper Therapeutics is in Stage 4, the downtrend phase, now in week 3 (since Oct 6, 2026). It closed at $0.50, 79.3% below its 52-week high and below its 200-day average, which is falling.

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. More about the company

$0.50

+2.65% today

$16.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is JSPR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S3 17w

S4 21w

S4 57w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 21w → S1 5w → S2 13w → S3 17w → S4 4w → S1 8w → S2 1w → S1 1w → S4 21w → S1 5w → S4 57w → S1 6w → S4 2w current

Total tracked: 165 weeks across 14 stage runs.

JSPR among Biotechnology470th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…470	JSPRJasper Therapeutics, Inc. Class A	Stage 4 · wk 3	11	−12.5%

vs 52W High

-79.3%

$0.34 lo$2.40 hi

79.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-44.0%

200 DMA: $0.89 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.15x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-12.5%

-27.9%

-45.2%

YTD

-73.0%

-80.5%

Scan Membership

Breakout Watch

Latest: 2024-12-30

7 appearances in last 60 days. First seen: 2020-12-30.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.15x

2026-10-21S4

Wk 3 · Vol 0.71x

2026-10-20S4

Wk 3 · Vol 0.73x

2026-10-19S4

Wk 2 · Vol 0.77x

2026-10-16S4

Wk 2 · Vol 0.48x

2026-10-15S4

Wk 2 · Vol 0.74x

2026-10-14S4

Wk 2 · Vol 1.20x

2026-10-13S4

Wk 2 · Vol 0.84x

2026-10-12S4

Wk 1 · Vol 0.65x

2026-10-09S4

Wk 1 · Vol 0.50x

2026-10-08S4

Wk 1 · Vol 0.70x

2026-10-07S4

Wk 1 · Vol 0.70x

Moving averages & range

50 DMA

$0.63

200 DMA

$0.89

52W High

$2.40

52W Low

$0.34

5D Low

$0.48

Resistance levels (recent highs)

20d High

$0.63

60d High

$0.89

120d High

$0.99

250d High

$2.37

Next resistance

+26.2%

to 20d High

Dividend Yield

0.00%

P/B 9.9

Jasper Therapeutics: quick answers

What stage is Jasper Therapeutics in?

As of Oct 22, 2026, Jasper Therapeutics (JSPR) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Jasper Therapeutics in an uptrend?

No. Jasper Therapeutics is in a Stage 4 downtrend. It trades 44.0% below its 200-day average, which is falling.

How far is Jasper Therapeutics from its 52-week high?

Jasper Therapeutics closed at $0.50 on Oct 22, 2026, 79.3% below its 52-week high of $2.40. Its 52-week low is $0.34.

How has Jasper Therapeutics performed over the past year?

As of Oct 22, 2026, Jasper Therapeutics is down 80.5% over the past year and down 73.0% so far in 2026.

Which sector and industry is Jasper Therapeutics in?

Jasper Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.